Our Work

About OvaCure

OvaCure is a scientific innovation incubator, accelerating curative cancer treatments in the fight against ovarian cancer. Not-for-profit. OvaCure initiates and accelerates innovative treatment methods with breakthrough potential that can lead to life prolonging or curative treatment for women with ovarian cancer. By partnering with the world’s leading experts, OvaCure acts as a unique catalyst in accelerating curative treatments and deliver these methods faster to patients.

The motivation behind the establishment of OvaCure is to create an optimal environment for leading international experts within gynaecology, immunotherapy and oncology, to meet and share their knowledge, experience and innovative ideas. When bringing together this extensive experience and knowledge, OvaCure fosters partnerships in order to expand the research field and break down the silos of specialties within the health care sector. This creates innovative clinical projects that would otherwise not have existed.

VISION

To cure ovarian cancer.

MISSION

To initiate, develop and accelerate breakthrough treatments through the world’s best clinical research projects, ultimately leading to a cure for ovarian cancer. We strive for scalability to other types of cancers.

STRATEGY

To bring together the world´s most internationally-renowned professionals in science, medical research, governments, NGOs and foundations. Through this, OvaCure works as an incubator for innovative new projects and partnerships to be initiated, developed and accelerated.

 

Added value by OvaCure

OvaCure's project criteria


The OvaCure process

OvaCure establishes strategic and innovative partnerships between the best Danish and international competencies within medicine, research, policy makers, NGOs and foundations. OvaCure acts as a catalyst to identify, develop, initiate and drive innovative research projects with breakthrough potential. By strengthening initiatives already active within these areas, OvaCure establishes a closer dialogue between scientists, clinicians and physicians. The OvaCure process promotes innovation, synergy and multidisciplinary knowledge sharing across all aspects of patient care.

  The OvaCure Process accelerates the most promising treatment approaches to ovarian cancer patients - faster.

The OvaCure Process accelerates the most promising treatment approaches to ovarian cancer patients - faster.

The OvaCure process is kicked off each year by definition of the summit theme by the OvaCure Scientific and Clinical Advisory Board and Anticancer Fund. A select group of international experts are then invited to submit concept proposals addressing the Summit theme. The Scientific and Clinical Advisory Board then identify project proposals which have the greatest potential to life prolonging or curing treatment options for ovarian cancer patients. These concepts are presented at the annual OvaCure Innovation Summits, where the OvaCure Scientific and Clinical Advisory Board, Anticancer Fund and leading experts co-create, innovate and optimise proposals into working clinical projects, which are then offered financial support.


OvaCure Innovation Summit & Collaboration Labs

  OvaCure brings together scientists, clinicians and researchers from around the globe annual to co-create, collaborate and innovate ovarian cancer treatment approaches

OvaCure brings together scientists, clinicians and researchers from around the globe annual to co-create, collaborate and innovate ovarian cancer treatment approaches

The annual OvaCure Innovation Summits bring together leading international experts within ovarian cancer, immunotherapy, oncology and innovative technologies. At the summit, experts provide inspiration for and collaborate to develop clinical projects with the greatest potential to cure. OvaCure's Scientific and Clinical Advisory Board then co-create, innovate and invest in new research projects focusing on treatments with breakthrough potential to cure ovarian cancer. Specific criteria for selecting the participants ensures the highest level of expertise applied to each project. Research projects nominated must have the potential to be studied in clinical trials within a reasonable time frame, ensuring an efficient streamline from the laboratory to the patient.

In 2016 OvaCure launched the first Collaboration Labs, dedicated to accelerate existing pipeline projects. The labs offer international clinicians and researchers to further define the clinical design needed to initiate their projects. 

OvaCure Scientific and Clinical Advisory Board is committed to optimising the projects while OvaCure and Anticancer Fund are responsible for project managing. This ensures optimal and efficient use of funding. Results are reported and evaluated upon achieved milestone timelines. Projects supported by OvaCure are carried out at research centres where operations, personnel and facilities are already established with medical infrastructure as well as quality compliance systems.

 

OvaCure's Results to date

Screenshot 2016-12-07 21.35.59.png

Themes & Outcomes of OvaCure Innovation Summits and Collaboration Labs:

Summit theme 2014:

"To identify and develop high quality projects within immunotherapy and ovarian cancer and assist the implementation of relevant scientific research."

  • Development of "T-cell Infusion Project", launched in 2014

Summit theme 2015:

"Innovative Immunotherapy in Ovarian Cancer including combination and monotherapy."

  • Development of "T-cell Combination Project", launched in 2015
  • Development of "Personal T-cell Project", launched in 2015
  • Development of "Personal Vaccine Project", launched in 2016

SUMMIT THEME 2016:

“Innovative Personalised Immunotherapy Approaches in Ovarian Cancer”.

  • A new potential project is identified and in the process of being developed

Collaboration Lab 2016:

 “Can genetic screening of ovarian cancer patients lead to curative treatment options?”

  • Development of "Genetic-Match Project", launching at the end of 2016

Collaboration Lab 2016:

“Combined approaches in ovarian cancer - novel peptide vaccines, clinical antibodies and ACT with TILs.”